Emcure

Pune, India Founded: 1983 • Age: 43 yrs Listed
Developer, manufacturer, and markets a broad range of pharmaceutical products
Request Access
Report Incorrect Data
Page last updated

About Emcure

Emcure is a publicly listed company based in Pune (India) founded in 1983 by Sunil Rajanikant Mehta. Developer, manufacturer, and markets a broad range of pharmaceutical products. Emcure has raised $50 million across 2 funding rounds from investors including Blackstone and Bain Capital Private Equity. The company has 6,730 employees. Emcure has completed 1 acquisition, including International Pharmaceutical Generics. Emcure was last valued at $367.12 million in July 2006. Its website emcure.com draws about 30 thousand monthly visits. Its Indian entity Emcure Pharmaceuticals Limited reported revenue of ₹9,335 Cr. Emcure offers products and services including Formulations and Biologics. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Emcure was founded in 1983 in Pune, India, within the pharmaceutical sector. Pharmaceutical products are developed, manufactured, and marketed across therapeutic areas such as gynecology, cardiology, oncology, blood disorders, HIV, respiratory, CNS, and anti-infectives. Formulations, biologics, and active pharmaceutical ingredients are also produced. Operations focus on global distribution from the Indian base.

  • Headquarters Pune, India
  • Employees 6,730
  • Founders Sunil Rajanikant Mehta
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website emcure.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Emcure Pharmaceuticals Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹42,044 Cr

    EMCURE · NSE

  • Share Price
    ₹2,216.20

    -2.80% today

  • Revenue
    ₹9,204 Cr

    FY 2025-26 · +16.6% YoY

  • EBITDA
    ₹1,714 Cr

    Margin 18.6%

  • Net Profit
    ₹945 Cr

    FY 2025-26 · +48.3% YoY

  • P/E (TTM)
    37.7x

    P/B 7.9x

  • ROE
    20.0%

    ROCE 23.1%

  • Debt / Equity
    0.27

    Interest cover 11.1x

  • Total Equity Funding
    $50M (USD)

    in 2 rounds

  • Investors
    Blackstone

    & 1 more

  • Employee Count
    6,730
  • Investments & Acquisitions
    International Pharmaceutical Generics

Products & Services of Emcure

Emcure offers a comprehensive portfolio of products and services, including Formulations and Biologics.

Formulations
Pharmaceutical Products

Formulations are developed and manufactured by Emcure for various therapeutic uses, enabling the provision of affordable healthcare solutions.

Biologics
Biopharmaceuticals

Biologics are produced by Emcure for treating complex diseases, including biosimilars and novel therapies that support global health needs.

Apps and channels of Emcure

its YouTube channel Uncondition Yourself with Namita Thapar has 46.1K subscribers and 30 videos.

Uncondition Yourself with Namita Thapar
YouTube 46.1K subscribers 30 videos Howto & Style
Open channel

Videos from Emcure

The most watched videos on Emcure's YouTube channel, Uncondition Yourself with Namita Thapar (46.1K subscribers). Click a video to play it here.

Women's Health | Episode 52 | With Mahendra Singh Dhoni
204.8K views
Endometriosis | Episode 49 | With Shamita Shetty
123.2K views
Autism| Episode 42| With Dr. Anaita Hegde and Mrs. Archana Chandra
111K views
Fatty Liver | Episode 43 | With Dr. Samir Shah
110.7K views

More on Uncondition Yourself with Namita Thapar.

Funding Insights of Emcure

Emcure has successfully raised a total of $50M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $50M
  • Total Rounds 2
  • First Round $50M

    (Jul 2006)

  • Investors Count 2

All 2 funding rounds of Emcure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2013Unspecified––
Bain Capital Private Equity
Jul 2006$50MPrivate Equity Round$367.12MBlackstone
–
Valuation history
DateValuationStage
Jul 2006$367.12M••••••••

Last known valuation $367.12M (Jul 2006). 2 investors in total: 2 institutional.

Investors in Emcure

Emcure has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Blackstone and Bain Capital Private Equity.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Bain Capital Private Equity
Private investment firm managing assets and expanding into equity, credit, and real estate services.
1984baincapitalprivateequity.comLondon, United Kingdom
Blackstone
Diversified investment management is provided across multiple asset classes.
1985blackstone.comNew York, United States
Premium access

Investor details for Emcure

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Emcure Pharmaceuticals Limited (Emcure)

Emcure Pharmaceuticals Limited is the primary company behind Emcure. The board of Emcure Pharmaceuticals Limited currently have 10 directors; the longest-serving is Satish Ramanlal Mehta, appointed in 1981. 25 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Satish Ramanlal Mehta
DIN 00118691
Managing Director16 Apr 198145 yrs 6 moEmcure Pharmaceuticals Limited
Mukund Keshao Gurjar
DIN 00026843
Whole-time director23 Jul 200125 yrs 3 moEmcure Pharmaceuticals Limited
Sunil Rajanikant Mehta
DIN 00118469
Whole-time director05 Jun 201313 yrs 5 moEmcure Pharmaceuticals Limited
Namita Vikas Thapar
DIN 05318899
Whole-time director28 Jul 201412 yrs 3 moEmcure Pharmaceuticals Limited
Shailesh Kripalu Ayyangar
DIN 00268076
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Vijay Keshav Gokhale
DIN 09134089
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Vidya Rajiv Yeravdekar
DIN 02183179
Director16 Apr 20215 yrs 6 moEmcure Pharmaceuticals Limited
Samit Satish Mehta
DIN 00332562
Whole-time director28 Jul 20224 yrs 3 moEmcure Pharmaceuticals Limited
Chinnadharavaram Sundaresan Muralidharan
DIN 00014740
Director01 Apr 20267 moEmcure Pharmaceuticals Limited
Raman Pillai Raghu Kumar
DIN 01983106
Director06 Aug 20263 moEmcure Pharmaceuticals Limited

People of Emcure

3 people are tracked at Emcure (3 in leadership); the tracked headcount is 6,730.

NameRoleGroup
Sunil Rajanikant Mehta
FounderLeadership
Mukund Keshao Gurjar
Leadership
Mahesh Nathalal Shah
Leadership
Premium access

Complete people profiles for Emcure

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Emcure

Emcure is a publicly listed company on the NSE with ticker symbol EMCURE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Jul 2024
  • Listed onBSE: 544210 · NSE: EMCURE
  • Listed entityEmcure Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE168P01015
  • Share price₹1,866.20 (-0.13% on the day) · 2026-10-14
  • Market capitalisation₹35,437 Cr
  • Price to earnings35.0
  • EPS (diluted, trailing year)₹53.35
  • Dividend yield0.19%
  • Volume (last session)157,573

Financials of Emcure

Exchange-reported figures of Emcure Pharmaceuticals Limited, the listed company behind Emcure (NSE: EMCURE).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,204 Cr
+16.6% YoY
EBITDA
₹1,714 Cr
+17.5% YoY
Profit After Tax
₹945 Cr
+48.3% YoY
Net Worth
₹4,950 Cr
+11.3% YoY
Total Assets
₹6,609 Cr
+9.8% YoY
Total Debt
₹1,521 Cr
+48.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Profit before tax1,287971727747973652105
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Balance sheet
Total assets6,6096,0205,8115,0894,4454,9664,686
Net worth4,9504,4462,9522,5011,9882,2731,912
Total debt1,5211,0232,3352,3342,2172,3102,327
Cash & bank148165232458313524164
Net working capital2,7072,3872,1022,2921,8481,9151,429
Cash flow
Cash from operations9448521,097747768704500
Cash from investing(1,175)(96.05)(715)(468)(574)(256)(168)
Cash from financing343(814)(164)(145)(152)(189)(301)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Profit before tax944428200212616557225
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
Balance sheet
Total assets5,3723,9383,5933,6673,4264,0113,202
Net worth3,7113,0241,9351,8421,7132,3021,915
Total debt1,5978571,5951,7731,5791,6651,243
Cash & bank16.8813.8032.1214147.8826139.22
Net working capital1,5031,0089881,2201,2741,3921,170
Cash flow
Cash from operations424558585505428775385
Cash from investing(947)(438)(173)(271)(394)(836)(169)
Cash from financing526(49.25)(288)(54.52)(343)30.97(45.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,8202,5802,4702,3632,2702,1012,1161,963
Revenue growth (YoY)+24.3%+22.9%+16.7%+20.4%+13.4%+15.7%--
Other income3.252.0714.291.853.123.704.453.90
EBITDA588532480455475413392355
EBITDA margin+20.8%+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%
Depreciation11011010610510599.4696.8496.81
Interest35.5831.5446.4037.9832.5426.7639.0331.78
Profit before tax446394341314341291261230
Tax12110197.4482.4290.0575.9763.3773.83
Net profit325292244231251215197156
EPS (₹)17.1415.5012.8412.1612.8510.929.978.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
Other income13172.7956.9945.9163.4733.8882.31
Total expenses7,4896,4385,4384,8114,5254,0104,448
Employee cost1,5521,4461,2921,1171,0129031,106
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Depreciation415384312260245250321
Interest144176237214176155257
Profit before tax1,287971727747973652105
Tax3462642001852702334.73
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus4,7604,2572,7712,3201,8072,0921,731
Shareholders' funds (net worth)4,9504,4462,9522,5011,9882,2731,912
Minority interest26.6419516914912794.9972.41
Secured loans1,2047301,7231,8831,8001,9552,513
Unsecured loans317293612452418355(187)
Total debt1,5211,0232,3352,3342,2172,3102,327
Total liabilities6,6096,0205,8115,0894,4454,9664,686
Assets
Gross block5,9525,4385,0523,8023,4723,2493,523
Net block3,3193,1973,1252,1472,0442,1882,382
Capital work in progress273177159411320302485
Investments19.7095.3831825.0025.000.000.00
Inventories2,3981,9321,5251,3831,4491,5141,173
Sundry debtors2,5632,0021,8591,6481,3091,4751,145
Cash & bank balances148165232458313524164
Loans & advances504380344346353204221
Total current assets5,6124,4803,9603,8363,4243,7172,703
Total current liabilities2,9052,0931,8581,5441,5761,8021,274
Net working capital2,7072,3872,1022,2921,8481,9151,429
Total assets6,6096,0205,8115,0894,4454,9664,686
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(14.31)43.99(175)(308)(350)(609)(641)
Net cash from operating activities9448521,097747768704500
Net cash from investing activities(1,175)(96.05)(715)(468)(574)(256)(168)
Net cash from financing activities343(814)(164)(145)(152)(189)(301)
Net change in cash112(58.30)21913441.8725931.86
Closing cash148165232458313524164
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%-
EBITDA growth+17.6%+19.6%+3.8%-11.7%+30.0%+70.4%-
PBT growth+32.5%+33.6%-2.7%-23.2%+49.2%+519.1%-68.1%
Net income growth+48.3%+26.6%-6.2%-19.0%+57.2%+165.2%-
Revenue CAGR (3Y)+15.4%+10.5%+9.8%+5.8%+7.5%--
EBITDA CAGR (3Y)+13.4%+3.1%+6.0%+25.1%+28.6%--
Profitability & leverage
Net income margin+10.2%+9.0%+7.9%+9.4%+12.0%+8.3%+2.0%
Return on capital employed+23.1%+20.0%+18.2%+20.8%+25.0%+21.1%+10.4%
Return on net worth+20.0%+19.1%+19.4%+25.0%+33.0%+20.1%+9.4%
Debt / equity0.270.450.861.011.061.111.19
Long-term debt / equity0.100.190.340.380.360.390.42
Interest cover11.0616.3626.1423.3516.2220.0491.77
Efficiency & per share
Fixed asset turnover1.621.511.501.651.741.491.52
Inventory turnover4.254.574.584.233.953.754.39
Debtors turnover4.034.093.804.054.213.844.77
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)261.09234.65162.97138.30109.90125.68105.72
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,6681,4511,4681,4181,2611,0971,2781,029
Revenue growth (YoY)+32.3%+32.3%+14.8%+37.9%+14.1%+13.0%--
Other income33.5425.0334.5213822.7521.5222.4019.41
Total expenses1,2721,1111,0961,1471,0368721,034904
EBITDA396340372271225224245124
EBITDA margin+23.8%+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%
Depreciation65.0163.1763.0462.1461.7459.8256.9156.65
Interest32.4232.7836.8733.1527.7120.5424.0719.93
Profit before tax33226930631415816618667.24
Tax83.9568.5772.5755.5140.2742.8846.4917.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
Other income312142138125133112138
Total expenses4,2463,7593,0652,6752,5932,4291,996
Employee cost821782706649604551545
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Depreciation247225205179166156155
Interest118113166167145123137
Profit before tax944428200212616557225
Tax21111139.0852.2717013749.47
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus3,5212,8351,7541,6611,5322,1211,734
Shareholders' funds (net worth)3,7113,0241,9351,8421,7132,3021,915
Secured loans8102511,4161,6691,5791,5971,191
Unsecured loans7876061801040.0067.1852.59
Total debt1,5978571,5951,7731,5791,6651,243
Total liabilities5,3723,9383,5933,6673,4264,0113,202
Assets
Gross block3,3233,1542,9532,4722,0312,0131,762
Net block1,7541,7591,7181,4331,1511,2781,166
Capital work in progress12299.11106253239192326
Investments1,424678684690563864408
Inventories1,2071,038770710730622444
Sundry debtors1,5351,1911,1031,0541,0099991,138
Cash & bank balances16.8813.8032.1214147.8826139.22
Loans & advances283218218234354334186
Total current assets3,0412,4602,1232,1402,1422,2151,808
Total current liabilities1,5381,4521,135919868824637
Net working capital1,5031,0089881,2201,2741,3921,170
Total assets5,3723,9383,5933,6673,4264,0113,202
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(17.53)(88.91)(213)(393)(84.29)(54.35)(225)
Net cash from operating activities424558585505428775385
Net cash from investing activities(947)(438)(173)(271)(394)(836)(169)
Net cash from financing activities526(49.25)(288)(54.52)(343)30.97(45.87)
Net change in cash2.5171.38124180(309)(29.94)170
Closing cash16.8813.8032.1214147.8826139.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-
EBITDA growth+60.1%+44.1%+0.1%-45.6%+9.6%+91.2%-
PBT growth+120.8%+114.0%-5.9%-65.6%+10.6%+148.1%-39.3%
Net income growth+180.4%+65.1%-1.5%-63.1%+3.0%+108.6%-
Revenue CAGR (3Y)+19.1%+9.0%+3.5%+9.4%+11.4%--
EBITDA CAGR (3Y)+32.1%-7.8%-15.8%+4.5%+14.1%--
Profitability & leverage
Net income margin+14.0%+7.2%+4.6%+5.2%+13.2%+13.3%+7.4%
Return on capital employed+22.8%+14.4%+10.1%+10.7%+20.5%+18.9%+13.1%
Return on net worth+21.8%+12.8%+8.5%+9.0%+22.3%+20.0%+11.3%
Debt / equity0.360.490.890.940.790.690.67
Long-term debt / equity0.220.240.340.340.290.280.26
Interest cover15.7528.3772.9365.7323.0821.6861.18
Efficiency & per share
Fixed asset turnover1.621.441.291.381.731.671.43
Inventory turnover4.674.854.734.315.015.925.06
Debtors turnover3.853.823.243.013.372.952.32
EPS (₹)38.6616.748.888.8524.7123.259.69
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)195.72159.61106.82101.8494.69127.27105.86

Investments & Acquisitions by Emcure

Emcure has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include International Pharmaceutical Generics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
International Pharmaceutical Generics
Generic drugs are manufactured for international distribution.
ipgenerics.comOttawa, Canada2005Jan 2016••••
Premium access

Complete acquisition details for Emcure

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Emcure

6 dated milestones of Emcure across 41 years, from founding to its latest funding, stage changes and deals.

  1. Founded Emcure is founded.
  2. Funding First funding round of $50.0M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Unspecified,.
  5. Acquisition Acquires International Pharmaceutical Generics.
  6. IPO Lists on the stock exchange (IPO).

Web traffic of Emcure

The website of Emcure (emcure.com) receives about 30.1K visits a month and ranks #995,771 among all websites worldwide, #1,221 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    30.1K

    ▲ 5.2% vs previous month

  • Unique visitors
    14.4K

    per month

  • Global rank
    #995,771

    among all websites

  • Category rank
    #1,221

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Emcure. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ajanta Pharma
ajantapharma.com
100%
20.1K#1,412,069View details
Natco Pharma
natcopharma.co.in
90%
19.8K#1,133,324View details
Lupin
lupin.com
87%
216.4K#208,025View details
Sms Pharmaceuticals
smspharma.com
86%
3K#2,783,668View details
Akums
akums.in
86%
25.5K#1,037,095View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 24 similar websites and full traffic analytics for Emcure

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 24 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Emcure (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Emcure

EMCURE: Q2 CONS NET PROFIT 3.3B RUPEES VS 2.44B (YOY)
Exchange Update • 7 days ago
EMCURE: Q2 REVENUE 28B RUPEES VS 22.7B (YOY)
Exchange Update • 7 days ago
EMCURE: Q2 EBITDA 5.87B RUPEES VS 4.7B (YOY); Q2 EBITDA MARGIN 20.84% VS 20.94% (YOY)
Exchange Update • 7 days ago
EMCURE: Rs. 28.98 Crores NSE Block Trade; for ~ 152,544 Shares, at Rs. 1900.10
Exchange Update • 1 month ago
Emcure Pharmaceuticals Ltd.: Rs. 17.47 Crores NSE Block Trade; for ~ 90,289 Shares, at Rs. 1934.50
Exchange Update • 1 month ago
Buzzing Stocks: Emcure Pharma gains 3% on USFDA EIR; PFC slips 3% after mixed Q1 earnings
Moneycontrol • 3 months ago
Emcure to double down on complex generics, biosimilars, ARVs, says COO Samit Mehta
Moneycontrol • 3 months ago
Emcure Pharma shares hits 52-week high post USFDA EIR for Gujarat facility
Moneycontrol • 3 months ago
Buy Emcure; target of Rs 2300: Motilal Oswal
Moneycontrol • 3 months ago
EMCURE: Q1 FY 2027 saw 22.8% revenue and 35.4% PAT growth, with margin expansion and strong global momentum
Quartr • 3 months ago
Premium access

Complete news archive for Emcure

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Emcure on our blog

Frequently Asked Questions about Emcure

Emcure was founded in 1983 and raised its 1st funding round 23 years after it was founded.

Emcure is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.

Emcure is a funded company, having raised a total of $50M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $50M, raised on Jul 2006.

Emcure has 6,730 employees.

The primary company behind Emcure, Emcure Pharmaceuticals Limited, reported revenue of ₹9,335 Cr for FY 2026, up 17% year on year.

Emcure was founded in 1983 in Pune, India, within the pharmaceutical sector. Pharmaceutical products are developed, manufactured, and marketed across therapeutic areas such as gynecology, cardiology, oncology, blood disorders, HIV, respiratory, CNS, and anti-infectives. Formulations, biologics, and active pharmaceutical ingredients are also produced. Operations focus on global distribution from the Indian base.

Emcure offers Formulations and Biologics.

Yes, Emcure is publicly traded on NSE under the ticker symbol EMCURE.

Emcure has made 1 acquisition, including International Pharmaceutical Generics.

Emcure has 2 investors. Key investors include Blackstone, and Bain Capital Private Equity.

The valuation of Emcure is $367.12M as of Jul 2006.

Emcure operates through Emcure Pharmaceuticals Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available